Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | PI4KA | P42356 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17140935 | 0.82 | PDK2 (0.38) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL13666577 | 0.80 | ALDH1A1 (0.47) | PDK2MAPTKDM4AMAPK1MEN1 | |
| SCHEMBL20327068 | 0.80 | MTOR (0.39) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL1976172 | 0.78 | PIK3CD (0.43) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL7872383 | 0.78 | TDP1 (0.44) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL22182995 | 0.78 | NNMT (0.52) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL995902 | 0.78 | ALDH1A1 (0.47) | MAPTCA12CA1CA2CA4 | |
| SCHEMBL30753596 | 0.78 | ALDH1A1 (0.47) | MAPTCA12CA1CA2CA4 | |
| SCHEMBL28015545 | 0.78 | ALDH1A1 (0.47) | MAPTCA12CA1CA2CA4 | |
| SCHEMBL3004644 | 0.77 | MTOR (0.41) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-12312341-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240300939-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| US-12084434-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| CN-117813293-A | Urea derivatives useful for the treatment of cancer | 蝎子疗法股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4334298-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | Scorpion Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240076289-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11897871-B1 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2023-01-19 | — | — | US | disclosed |
| WO-2022265993-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022265993-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2019079373-A1 | PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-04-25 | — | — | WO | disclosed |
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-2390254-A1 | NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-20110257678-A1 | VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF | INCEPT LLC (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2010010184-A1 | [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | GPR119, GPR139, HCAR1 | PIK3CD 2171/4885PIK3CA 1721/4885PIK3CB 1895/4885 |
| US-20240300939-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | PIK3CA, PIK3CG, PIK3CD | PIK3CD 3/4885PIK3CA 1/4885PIK3CB 4/4885 |
| US-11897871-B1 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | PIK3CD 4/4885PIK3CA 1/4885PIK3CB 6/4885 |
| US-12312341-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | PIK3CD 4/4885PIK3CA 1/4885PIK3CB 6/4885 |
| US-20240076289-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | PIK3CD 4/4885PIK3CA 1/4885PIK3CB 6/4885 |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | PIK3CD 4/4885PIK3CA 1/4885PIK3CB 6/4885 |
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | DTYMK, TBKBP1, NFKBIA | PIK3CD 347/4885PIK3CA 346/4885PIK3CB 269/4885 |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | PIK3CD 4/4885PIK3CA 1/4885PIK3CB 6/4885 |
| US-12084434-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | PIK3CD 4/4885PIK3CA 1/4885PIK3CB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.